Search
From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need
From Syncona's Capital Markets Day, Founder and CEO Catherine Pickering walks us through the science of roginolisib and describes the current landscape for uveal melanoma. She discusses her phase 2, which is approaching a key readout.
Mar 19
Biotech CEO Sisterhood: Catherine Pickering is leading iOnctura, which is focused on solving the problem of cancer resistance both at the tumor and around its environment
She discusses the approach and the company's lead program, which targets PI3Kδ. Plus, and autotaxin program for cancer and TGF-β.
Sep 4, 2025
.png){kind=logo}
